Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CBP-1019 by Coherent Biopharma for Esophageal Cancer: Likelihood of Approval
CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
CBP-1019 by Coherent Biopharma for Pancreatic Cancer: Likelihood of Approval
CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
CBP-1019 by Coherent Biopharma for Colorectal Cancer: Likelihood of Approval
CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
CBP-1019 by Coherent Biopharma for Lung Cancer: Likelihood of Approval
CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Lung Cancer. According to GlobalData, Phase...
CBP-1019 by Coherent Biopharma for Breast Cancer: Likelihood of Approval
CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Breast Cancer. According to GlobalData, Phase...